EN DE
Watch HC SURGICAL SPECIALISTSLIMITED for free: we tell you when fair value or trend changes.
Data-driven stock valuation

HC SURGICAL SPECIALISTSLIMITED (1B1) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of HC SURGICAL SPECIALISTSLIMITED stock S$0.71, price S$0.35, upside +102.9%, quality 83 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG · ISIN SG1DC2000004

HS HC SURGICAL SPECIALISTSLIMITED logo Thin data Nov 15, 2026

HC SURGICAL SPECIALISTSLIMITED

1B1 · SG

Cheap (51% below fair value), strong company and rising price: meets all 3 rules.

Get notified free when this changes
Fair value 0.7100 SGD · Strongly undervalued 
Quality 83/100 
Rising price (uptrend) 
Healthy Growth (revenue 5y +2.7 %/yr in SGD) 
Highly profitable · 35.3% net margin (TTM) 
Low debt 
Generates free cash flow 
6.0% dividend yield · Well covered
Ranks above peers (12/14) 
Even on cautious assumptions the value is 43% above the price (0.5000 SGD). 
Wide moat 87/100 · thin data
Thin data 
⚠ Small free float
Watch HC SURGICAL SPECIALISTSLIMITED for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.4439 SGD 0.2149 SGD Fair Value 0.7100 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range 0.2149 SGD – 0.4439 SGD · fair‑value band 0.5000 SGD – 0.9000 SGD · the 0.3500 SGD price screens below the 0.7100 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow HC SURGICAL SPECIALISTSLIMITED in your weekly email

Every Wednesday you see whether HC SURGICAL SPECIALISTSLIMITED is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

HC Surgical Specialists Limited, an investment holding company, provides medical services primarily in Singapore. The company provides endoscopic procedures, including gastroscopies and colonoscopies; and general surgery services with a focus on colorectal procedures in a network of clinics.

Show moreShow less

It also offers treatment services for other conditions, such as haemorrhoids, anal fissure, hernia, anal abscess, cholecystitis, anal fistula, appendicitis, colorectal cancer, lipomas, cysts, and gastric cancer, vein laser vascular, laparoscopy, and other general and specialized medical services.

In addition, the company provides orthopedic services comprising joint pain, sports injuries, osteoarthritis, rotator cuff tears, trigger finger, wounds/lumps, tenosynovitis, tunnel syndrome, bumps, joint replacement, arthroscopic surgery, knee osteotomy, realignment surgery, endoscopic spine surgery, disc replacements, spinal decompression, fractures, and orthobiologic injections.

Further, it provides home care services, which include medical, nursing, physiotherapy, speech therapy, occupational therapy, and ambulance services; health screening, management of acute and chronic conditions, and pre-employment check-up; public health preparedness clinic scheme, swab and send home program, community health assist scheme, and COVID-19 swab test services.

Additionally, the company offers diagnostic tests that comprise blood tests, X-Rays, ultrasound, CT scans, and MRIs. HC Surgical Specialists Limited was incorporated in 2015 and is based in Singapore.

Stock analysis

HC SURGICAL SPECIALISTSLIMITED (1B1) currently trades at 0.3500 SGD, while our model-based Fair Value estimate is 0.7100 SGD, implying the stock looks roughly 51% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 0.9900 SGD per share, and 20 of the 24 models we run sit above the 0.3500 SGD price.

Bear case: the Dividend Discount group reads lowest at 0.2150 SGD, and 4 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.5000 SGD (bear) to 0.9000 SGD (bull), the price of 0.3500 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 83/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

HC SURGICAL SPECIALISTSLIMITED reported revenue of 19.1M SGD in FY2025 versus 23.4M SGD in FY2021, a compound −4.9%/yr. Reported net income was 8.4M SGD in FY2025, compounding +1.3%/yr from FY2021.

Key figures

Market cap 53.7M SGD (≈ $41.7M) Micro · P/E ratio 7.0 · P/S ratio 2.71 · EPS (TTM) 0.0500 SGD · Dividend yield 6.0% · Net margin 35.3% · Return on equity 34.8% · Return on assets (EBIT) 26.2% (4-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 87 out of 100 (low confidence).

What moves the price

The share trades about 13% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 103%, 1B1 screens cheaper than that median.

Fair Value models

Bear 0.5000 SGD Fair Value 0.7100 SGD Bull 0.9000 SGD
Price 0.3500 SGD · Upside +102.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (0.0290 SGD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 0.4900 SGD 0.6800 SGD 0.9500 SGD 81
Growth DCF 0.5000 SGD 0.6800 SGD 0.9100 SGD 79
5Y EBITDA Exit 0.5100 SGD 0.7700 SGD 1.06 SGD 75
All 24 models by family
DCF Models
FCF DCF 0.4900 SGD 0.6800 SGD 0.9500 SGD 81
5Y Revenue Exit 0.3600 SGD 0.4900 SGD 0.6600 SGD 73
5Y EBITDA Exit 0.5100 SGD 0.7700 SGD 1.06 SGD 75
5Y P/E Exit 0.7000 SGD 1.11 SGD 1.52 SGD 71
10Y Revenue Exit 0.4000 SGD 0.5300 SGD 0.6800 SGD 68
10Y EBITDA Exit 0.5000 SGD 0.7100 SGD 0.9700 SGD 69
10Y P/E Exit 0.6100 SGD 0.9300 SGD 1.30 SGD 64
Earnings-Based
Graham-Dodd 0.3700 SGD 0.9100 SGD 1.17 SGD 65
PEG = 1.0 0.3000 SGD 0.4200 SGD 0.5500 SGD 57
EPV 0.3500 SGD 0.4000 SGD 0.4400 SGD 74
Dividend Discount
Gordon GGM 0.1400 SGD 0.2300 SGD 0.3500 SGD 67
DDM Multi-Stage 0.1400 SGD 0.2000 SGD 0.2700 SGD 67
Multiples
P/E Multiple 0.9100 SGD 1.21 SGD 1.51 SGD 63
P/S Multiple 0.3300 SGD 0.4400 SGD 0.5500 SGD 58
P/B Multiple 0.3900 SGD 0.5200 SGD 0.6400 SGD 55
EV/EBIT 0.5600 SGD 0.7300 SGD 0.9000 SGD 66
EV/EBITDA 0.6000 SGD 0.7800 SGD 0.9700 SGD 67
EV/Revenue 0.2900 SGD 0.4100 SGD 0.5200 SGD 54
Asset-Based
NCAV (Graham) 0.0100 SGD 0.0100 SGD 0.0200 SGD 52
Growth DCF
Growth DCF 0.5000 SGD 0.6800 SGD 0.9100 SGD 79
Rev-Margin DCF 0.3600 SGD 0.5000 SGD 0.6600 SGD 73
Economic Profit
Residual Income 0.2900 SGD 0.3500 SGD 0.5600 SGD 74
ROIC Compounder 0.3600 SGD 0.4300 SGD 0.5000 SGD 72
Growth Earnings
Growth-Adj P/E 0.6900 SGD 0.9900 SGD 1.28 SGD 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 83/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 90
How much profit the company makes from its sales and capital
Quality Growth 66
Are margins and returns getting better?
Cashflow 81
Do the profits arrive as real cash?
Financial strength 93
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 86
How calm the share price moves, does not count
Price momentum 41
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 34
Distance to the 52-week high, does not count
New shares 78
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 73/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Start year 2020 (pandemic). Over 10 years: +10.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +4.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.1%
Dividend (yield on the price)6.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.35% → 37%
⚠ Rate on operating basis: 2025 sits 120% above its own trend.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−10.0%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about −11.8% a year for the price.

Watch 1B1, get fair value alerts →

Compare HC SURGICAL SPECIALISTSLIMITED with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 150 stocks

Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 83 · Top 25%
Fair Value upside +102.9% · Top 25%
Profitability
Return on equity (12 months) 34.8% · Top 25%
Return on assets 30.9% · Top 25%
Net margin (12 months) 35.3% · Top 25%
Operating margin (12 months) 23.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −7.5% · Bottom 25%
Dividend yield (12 months) 6.0% · Top 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 7.0× · Cheapest 25%
P/B 2.56× · Pricier than median
P/S (12 months) 2.71× · Cheaper than median
Price / free cash flow (fiscal year) 8.0× · Cheapest 25%
EV/EBITDA 9.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 14
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)100 · sector 8
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)100 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥144.41 ¥164.66 +14% vs 1B1
IQVIA Holdings IQV $265.12 $291.63 +10% vs 1B1
Illumina, Inc ILMN $207.01 $227.71 +10% vs 1B1
Thermo Fisher Scientific Inc TMO $700.22 $686.04 −2% vs 1B1
Danaher Corporation DHR $233.02 $209.18 −10% vs 1B1
IDEXX Laboratories, Inc IDXX $704.23 $496.48 −30% vs 1B1
Lonza Group LONN CHF 670.20 CHF 259.80 −61% vs 1B1
Mettler-Toledo International Inc MTD $1,739 $655.06 −62% vs 1B1
Agilent Technologies, Inc A $173.96 $64.53 −63% vs 1B1
Waters Corporation WAT $460.25 $91.26 −80% vs 1B1

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

HC SURGICAL SPECIALISTSLIMITED: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "HC SURGICAL SPECIALISTSLIMITED Fair Value". https://www.fairvalue-calculator.com/stock/1B1

Frequently asked questions

Is HC SURGICAL SPECIALISTSLIMITED (1B1) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of 0.7100 SGD versus a price of 0.3500 SGD, about +103% upside (undervalued).
What is the fair value of 1B1?
Our model-based fair value for HC SURGICAL SPECIALISTSLIMITED is 0.7100 SGD (as of Nov 15, 2026), built from audited fundamentals. The current price: 0.3500 SGD.
What is the quality score of 1B1?
HC SURGICAL SPECIALISTSLIMITED has a Quality Score of 83/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HC SURGICAL SPECIALISTSLIMITED (1B1)?
Our model-based price target is the fair value of 0.7100 SGD (as of Nov 15, 2026) from 24 valuation models. Cautious scenario 0.5000 SGD, optimistic scenario 0.9000 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the HC SURGICAL SPECIALISTSLIMITED stock forecast for 2026?
Our models put fair value at 0.7100 SGD, about +103% upside versus a price of 0.3500 SGD (undervalued). Cautious scenario 0.5000 SGD, optimistic scenario 0.9000 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of HC SURGICAL SPECIALISTSLIMITED (1B1)?
HC SURGICAL SPECIALISTSLIMITED reported trailing-twelve-month revenue of about 19.8M SGD (latest available figure, as of Nov 15, 2026).
Does HC SURGICAL SPECIALISTSLIMITED pay a dividend?
HC SURGICAL SPECIALISTSLIMITED currently shows a dividend yield of 6.00% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of HC SURGICAL SPECIALISTSLIMITED (1B1) and when is the ex-dividend date?
HC SURGICAL SPECIALISTSLIMITED pays a dividend of 0.021 SGD per share a year, a dividend yield of 6.0%. The last ex-dividend date was Oct 21, 2026. A dividend has been paid every year since at least 2017. The payout ratio is 42.0% of earnings. Free cash flow covers the dividend 2.09 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into HC SURGICAL SPECIALISTSLIMITED (1B1)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at HC SURGICAL SPECIALISTSLIMITED shrinks by 10.0 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 2.7 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of 1B1 use?
Our models discount HC SURGICAL SPECIALISTSLIMITED at 9.5 %: a base by market capitalisation (nano), country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HC SURGICAL SPECIALISTSLIMITED that is -10.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has HC SURGICAL SPECIALISTSLIMITED (1B1) delivered so far?
Over the past 5 years revenue at HC SURGICAL SPECIALISTSLIMITED grew 2.7 % a year. The price currently implies free-cash-flow growth of -10.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HC SURGICAL SPECIALISTSLIMITED (1B1) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into HC SURGICAL SPECIALISTSLIMITED (-10.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The free-cash-flow yield on the price is 12.56 %: that much free cash flow HC SURGICAL SPECIALISTSLIMITED produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HC SURGICAL SPECIALISTSLIMITED (1B1)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HC SURGICAL SPECIALISTSLIMITED it is 0.7100 SGD per share (as of Nov 15, 2026), against a price of 0.3500 SGD. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is HC SURGICAL SPECIALISTSLIMITED stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 1B1 trades below its calculated fair value: price 0.3500 SGD, fair value 0.7100 SGD, a gap of about +103% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1B1?
No. The price is what the market pays today (0.3500 SGD); the fair value is what the company's own numbers justify (0.7100 SGD). For HC SURGICAL SPECIALISTSLIMITED the two are 0.3600 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is HC SURGICAL SPECIALISTSLIMITED worth?
The market values HC SURGICAL SPECIALISTSLIMITED at about 53.7M SGD (market capitalisation, as of Nov 15, 2026). Per share that is 0.3500 SGD; our models calculate a fair value of 0.7100 SGD per share.
What do the bullish and bearish scenarios say about 1B1?
Our models span a range for HC SURGICAL SPECIALISTSLIMITED: cautious scenario 0.5000 SGD, base 0.7100 SGD, optimistic 0.9000 SGD per share (as of Nov 15, 2026, price 0.3500 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1B1?
HC SURGICAL SPECIALISTSLIMITED trades at a price-to-earnings ratio of 7.0 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.7100 SGD is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings: 11.6. Other multiples: P/B 2.6, P/S 2.7, EV/EBITDA 9.0.
How solid is the balance sheet of HC SURGICAL SPECIALISTSLIMITED (1B1)?
Balance-sheet figures for HC SURGICAL SPECIALISTSLIMITED (as of Nov 15, 2026): return on equity 34.8%. They feed the Quality Score of 83/100, which measures business quality independently of the share price.
How far is 1B1 from its 52-week high?
HC SURGICAL SPECIALISTSLIMITED trades at 0.3500 SGD, about 13% below its 52-week high of 0.4000 SGD and 7% above the low of 0.3265 SGD (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 0.7100 SGD is for.
Which stocks are comparable to HC SURGICAL SPECIALISTSLIMITED?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HC SURGICAL SPECIALISTSLIMITED stock attractive at the current price?
The data as of Nov 15, 2026: price 0.3500 SGD, calculated fair value 0.7100 SGD (+103%), Quality Score 83/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1B1 calculated?
We run HC SURGICAL SPECIALISTSLIMITED through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.7100 SGD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. HC SURGICAL SPECIALISTSLIMITED currently trades 51% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The closing price on Nov 16, 2026 was 0.3500 SGD. Our model-based fair value is 0.7100 SGD, about +103% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HC SURGICAL SPECIALISTSLIMITED right now?
The rarer combination: high quality (83/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (0.5000 SGD). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.5000 SGD to 0.9000 SGD) leaves room in how you read the outcome.

Key figures of HC SURGICAL SPECIALISTSLIMITED

How large is the market capitalisation of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The market capitalisation of HC SURGICAL SPECIALISTSLIMITED is 53.7M SGD (≈ $41.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The price-to-sales ratio of HC SURGICAL SPECIALISTSLIMITED is 2.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HC SURGICAL SPECIALISTSLIMITED (1B1)?
Earnings per share at HC SURGICAL SPECIALISTSLIMITED are 0.0500 SGD (price ÷ EPS = P/E 7.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The dividend yield of HC SURGICAL SPECIALISTSLIMITED is 6.0% (payout 42.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The net margin of HC SURGICAL SPECIALISTSLIMITED is 35.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The return on equity (ROE) of HC SURGICAL SPECIALISTSLIMITED is 34.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HC SURGICAL SPECIALISTSLIMITED (1B1)?
On an EBIT basis the return on assets of HC SURGICAL SPECIALISTSLIMITED is 26.2% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The operating margin of HC SURGICAL SPECIALISTSLIMITED is 23.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HC SURGICAL SPECIALISTSLIMITED (1B1)?
Revenue at HC SURGICAL SPECIALISTSLIMITED is down 7.5% versus a year earlier (3y avg −0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HC SURGICAL SPECIALISTSLIMITED (1B1)?
Earnings per share at HC SURGICAL SPECIALISTSLIMITED are down 40.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch HC SURGICAL SPECIALISTSLIMITED in the live analysis

One click puts HC SURGICAL SPECIALISTSLIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.